Simulations Plus Enters New Collaboration with Leading Animal Health Company

Rhea-AI Summary

Simulations Plus has announced a new funded collaboration with a major animal health company to enhance its GastroPlus platform. This partnership aims to validate existing animal physiologically based pharmacokinetic (PBPK) models and introduce new species to the platform. The collaboration will bolster veterinary medicine and food production research, promoting animal welfare and public health. Leaders from Simulations Plus emphasized the significance of this expansion into animal health markets, aiming to develop innovative modeling tools.

Positive

• New collaboration with a large animal health company to enhance GastroPlus platform.
• Focus on validating current PBPK models and adding new species.
• Expansion into animal health markets supports veterinary medicine and food production.

Negative

• None.

Partnership will expand virtual animal models to support veterinary medicine and next-generation alternatives to animal testing

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new funded collaboration with a large animal health company to both validate current animal physiologically based pharmacokinetic (PBPK) models and to add critical new species to the GastroPlus^® platform.

Dr. Viera Lukacova, division chief scientific officer of Simulations Plus, said: “Our GastroPlus software has pioneered the application of PBPK modeling to simulate the exposure of pharmaceutical drugs and environmental chemicals in animals, and the advanced methodologies available today have served as a foundational element for companies in their pursuit of impactful alternatives to animal testing. This new collaboration will extend GastroPlus functionality to modern animal agriculture and support veterinary medicine and food production research. We are excited to begin working with our partner and leverage their expertise and the unique data they will be sharing to develop the next generation of tools which will promote the health and welfare of animals and the general public.”

“Expansion of our technologies into animal health markets, and the academic laboratories and regulatory agencies which support and oversee them, is an important milestone for our company,” added John DiBella, division president, Simulations Plus. “The GastroPlus brand is incredibly strong, and I’m confident that the scientifically sound approaches taken by our talented team and our partner will result in valuable new models and best practice recommendations that will reinforce the platform’s position. The importance of these collaborations cannot be overstated, and we will continue to pursue future collaborations across our entire suite of software programs to drive innovation and advance modeling and simulation science.”

About Simulations Plus

Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005354/en/

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Hayden IR

Mr. Brian Siegel

346-396-8696

brian@haydenir.com

Source: Simulations Plus, Inc.

FAQ

What recent collaboration has Simulations Plus announced?

Simulations Plus announced a collaboration with a large animal health company to enhance its GastroPlus platform.

How will the new collaboration benefit veterinary medicine?

The collaboration will validate current animal PBPK models and support food production research, promoting animal welfare.

What is the goal of the new partnership for Simulations Plus?

The goal is to expand the functionality of the GastroPlus software and develop innovative modeling tools.

What does the collaboration involve?

The collaboration involves validating existing animal models and integrating new species into the GastroPlus platform.

How does this partnership impact the stock symbol SLP?

The announcement may positively impact SLP by reinforcing its position in the animal health market.